Premium
Tumor hypoglycemia
Author(s) -
Silverstein Murray N.
Publication year - 1969
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(196901)23:1<142::aid-cncr2820230118>3.0.co;2-0
Subject(s) - hypoglycemia , medicine , pathology , endocrinology , gastroenterology , insulin
The syndrome of hypoglycemia associated with neoplasia is now a well‐documented entity. At least 50% of the lesions have been hepatomas or fibre‐sarcomas and approximately 53% of them have been found in the retroperitoneal region or the liver. The outstanding feature of the tumors is their large size and weight. This syndrome in humans is well mirrored by the experimental model of hypoglycemia encountered in AKR mice with tumor BW5147. In most cases the hypoglycemia may be explained on the basis of increased glucose consumption by the large mass of neoplastic tissue and the secretion of tryptophan metabolites, which have a potent hypoglycemic action and may be responsible for the large bulk of tumors.